Repligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 28 2025
0mins
Should l Buy RGEN?
Source: NASDAQ.COM
Earnings Performance: Repligen (RGEN) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42, and showing a year-over-year increase from $0.43. The company has surpassed consensus EPS estimates three times in the last four quarters.
Revenue Growth: The company achieved revenues of $188.81 million for the quarter, surpassing the Zacks Consensus Estimate by 4.18% and increasing from $154.87 million a year ago, also topping revenue estimates three times in the last four quarters.
Stock Outlook: Despite an 11.9% increase in shares since the beginning of the year, Repligen is currently rated Zacks Rank #4 (Sell), indicating expected underperformance in the near future due to unfavorable earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Repligen operates, ranks in the top 37% of Zacks industries, suggesting that overall industry performance can significantly impact individual stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 121.790
Low
165.00
Averages
189.00
High
207.00
Current: 121.790
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Brown Capital Management Sells AppFolio Shares Worth $45.11 Million
- Share Sale Details: Brown Capital Management sold 189,819 shares of AppFolio in Q4 2026, valued at approximately $45.11 million, indicating a potential decline in confidence regarding the company's future performance.
- Holding Proportion Change: Following this transaction, AppFolio now represents only 2.9% of Brown Capital's 13F assets, suggesting a diminished significance in their investment portfolio that could influence future investment strategies.
- Market Performance Analysis: As of February 17, 2026, AppFolio shares were priced at $168.79, down 20.6% year-over-year and trailing the S&P 500 by 34.25 percentage points, reflecting a waning investor confidence in the stock.
- Investor Focus: The reduction in holdings by Brown Capital may relate to managing outflows or locking in gains, prompting investors to monitor AppFolio's customer retention rates and revenue growth per unit to assess its future growth potential.
See More
Brown Capital Sells AppFolio Shares Worth $45.11 Million
- Share Sale Details: On February 17, 2026, Brown Capital sold 189,819 shares of AppFolio, with an estimated transaction value of $45.11 million, indicating a strategic move to manage liquidity amid market fluctuations.
- Decline in Position Value: Following the sale, the quarter-end value of AppFolio's position decreased by $58.87 million, illustrating the dual impact of share reduction and price movement, which may affect investor confidence in the stock.
- Change in Holding Proportion: Post-sale, Brown Capital's remaining 152,123 shares now represent only 2.9% of its assets under management, removing AppFolio from its top five holdings, signaling a shift in investment strategy.
- Market Reaction: AppFolio's stock has fallen 21% over the past year, reflecting investor cooling towards high-multiple software companies, with future growth hinging on increasing managed units and revenue per unit through value-added services.
See More
Repligen Corporation Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Repligen reported Q4 2025 revenue of $198 million, an 18% year-over-year increase, with full-year revenue reaching $738 million and a 16% organic growth rate, reflecting robust performance in the bioprocessing market.
- 2026 Guidance: Management introduced revenue guidance for 2026 between $810 million and $840 million, representing 9% to 13% organic growth, despite a noted 2-point headwind from a gene therapy platform, indicating confidence in future prospects.
- Product Innovation and Market Expansion: The company launched new AVIPure resins and gained traction with the SoloVPE PLUS analytics platform, emphasizing successful cross-selling initiatives, with product line sales to key customers increasing 2.5 times since 2019, showcasing significant market penetration.
- Operational Efficiency Improvement: Management expects adjusted operating income for 2026 to be between $122 million and $130 million, with projected adjusted gross margins expanding to 53.6% to 54.1%, which will enhance the company's profitability in a competitive landscape.
See More
Repligen Q4 Earnings Exceed Expectations
- Earnings Highlights: Repligen reported a Q4 non-GAAP EPS of $0.49, beating expectations by $0.05, with revenue of $197.91 million reflecting an 18.1% year-over-year increase, surpassing market expectations by $5.68 million, indicating robust market performance and profitability.
- 2026 Financial Guidance: The company projects total revenue for 2026 to be between $810 million and $840 million, with a growth rate of 10% to 14%, and an organic growth forecast of 9% to 13%, reflecting confidence in future growth and optimistic market demand.
- Margin Expansion: Adjusted operating margin is expected to expand by 150 basis points to a range of 15.1% to 15.5% in 2026, which will further enhance the company's profitability and competitive position, supporting its long-term strategic objectives.
- Market Expectations Comparison: Although the projected EPS for 2026 is between $1.93 and $2.01, below the consensus estimate of $2.07, the company still demonstrates strong financial resilience and potential for sustained growth.
See More
Repligen Exceeds 2025 Revenue Expectations with Strong Growth
- Quarterly Revenue Growth: Repligen reported fourth-quarter revenue of $198 million, an 18% year-over-year increase with 14% organic growth, indicating strong momentum in orders and reinforcing the company's market position in bioprocessing technology.
- Impressive Annual Performance: The full-year 2025 revenue reached $738 million, a 16% increase compared to the previous year, surpassing the company's initial revenue and adjusted operating income guidance, reflecting the strong appeal of its differentiated product portfolio.
- Positive 2026 Outlook: The company anticipates 2026 revenue guidance between $810 million and $840 million, with growth rates of 10% to 14%, alongside expected adjusted operating margin expansion of 150 basis points at the midpoint, demonstrating confidence in future growth.
- Investment in APAC Market: In the fourth quarter, Repligen opened a new office in Singapore and expanded its footprint in Japan, aiming to enhance its market presence in the Asia-Pacific region to support future growth strategies.
See More
Repligen Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Repligen is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.44, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $192.23 million, reflecting a 14.7% year-over-year increase, which underscores the company's ongoing growth and strong market demand in the biopharmaceutical sector.
- Performance Beat Record: Over the past two years, Repligen has exceeded EPS and revenue estimates 63% of the time, demonstrating reliability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, indicating analyst divergence regarding the company's future performance, which may influence investor decisions.
See More
Brown Capital Management Sells AppFolio Shares Worth $45.11 Million
- Share Sale Details: Brown Capital Management sold 189,819 shares of AppFolio in Q4 2026, valued at approximately $45.11 million, indicating a potential decline in confidence regarding the company's future performance.
- Holding Proportion Change: Following this transaction, AppFolio now represents only 2.9% of Brown Capital's 13F assets, suggesting a diminished significance in their investment portfolio that could influence future investment strategies.
- Market Performance Analysis: As of February 17, 2026, AppFolio shares were priced at $168.79, down 20.6% year-over-year and trailing the S&P 500 by 34.25 percentage points, reflecting a waning investor confidence in the stock.
- Investor Focus: The reduction in holdings by Brown Capital may relate to managing outflows or locking in gains, prompting investors to monitor AppFolio's customer retention rates and revenue growth per unit to assess its future growth potential.
See More
Brown Capital Sells AppFolio Shares Worth $45.11 Million
- Share Sale Details: On February 17, 2026, Brown Capital sold 189,819 shares of AppFolio, with an estimated transaction value of $45.11 million, indicating a strategic move to manage liquidity amid market fluctuations.
- Decline in Position Value: Following the sale, the quarter-end value of AppFolio's position decreased by $58.87 million, illustrating the dual impact of share reduction and price movement, which may affect investor confidence in the stock.
- Change in Holding Proportion: Post-sale, Brown Capital's remaining 152,123 shares now represent only 2.9% of its assets under management, removing AppFolio from its top five holdings, signaling a shift in investment strategy.
- Market Reaction: AppFolio's stock has fallen 21% over the past year, reflecting investor cooling towards high-multiple software companies, with future growth hinging on increasing managed units and revenue per unit through value-added services.
See More
Repligen Corporation Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Repligen reported Q4 2025 revenue of $198 million, an 18% year-over-year increase, with full-year revenue reaching $738 million and a 16% organic growth rate, reflecting robust performance in the bioprocessing market.
- 2026 Guidance: Management introduced revenue guidance for 2026 between $810 million and $840 million, representing 9% to 13% organic growth, despite a noted 2-point headwind from a gene therapy platform, indicating confidence in future prospects.
- Product Innovation and Market Expansion: The company launched new AVIPure resins and gained traction with the SoloVPE PLUS analytics platform, emphasizing successful cross-selling initiatives, with product line sales to key customers increasing 2.5 times since 2019, showcasing significant market penetration.
- Operational Efficiency Improvement: Management expects adjusted operating income for 2026 to be between $122 million and $130 million, with projected adjusted gross margins expanding to 53.6% to 54.1%, which will enhance the company's profitability in a competitive landscape.
See More
Repligen Q4 Earnings Exceed Expectations
- Earnings Highlights: Repligen reported a Q4 non-GAAP EPS of $0.49, beating expectations by $0.05, with revenue of $197.91 million reflecting an 18.1% year-over-year increase, surpassing market expectations by $5.68 million, indicating robust market performance and profitability.
- 2026 Financial Guidance: The company projects total revenue for 2026 to be between $810 million and $840 million, with a growth rate of 10% to 14%, and an organic growth forecast of 9% to 13%, reflecting confidence in future growth and optimistic market demand.
- Margin Expansion: Adjusted operating margin is expected to expand by 150 basis points to a range of 15.1% to 15.5% in 2026, which will further enhance the company's profitability and competitive position, supporting its long-term strategic objectives.
- Market Expectations Comparison: Although the projected EPS for 2026 is between $1.93 and $2.01, below the consensus estimate of $2.07, the company still demonstrates strong financial resilience and potential for sustained growth.
See More
Repligen Exceeds 2025 Revenue Expectations with Strong Growth
- Quarterly Revenue Growth: Repligen reported fourth-quarter revenue of $198 million, an 18% year-over-year increase with 14% organic growth, indicating strong momentum in orders and reinforcing the company's market position in bioprocessing technology.
- Impressive Annual Performance: The full-year 2025 revenue reached $738 million, a 16% increase compared to the previous year, surpassing the company's initial revenue and adjusted operating income guidance, reflecting the strong appeal of its differentiated product portfolio.
- Positive 2026 Outlook: The company anticipates 2026 revenue guidance between $810 million and $840 million, with growth rates of 10% to 14%, alongside expected adjusted operating margin expansion of 150 basis points at the midpoint, demonstrating confidence in future growth.
- Investment in APAC Market: In the fourth quarter, Repligen opened a new office in Singapore and expanded its footprint in Japan, aiming to enhance its market presence in the Asia-Pacific region to support future growth strategies.
See More
Repligen Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Repligen is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.44, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $192.23 million, reflecting a 14.7% year-over-year increase, which underscores the company's ongoing growth and strong market demand in the biopharmaceutical sector.
- Performance Beat Record: Over the past two years, Repligen has exceeded EPS and revenue estimates 63% of the time, demonstrating reliability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, indicating analyst divergence regarding the company's future performance, which may influence investor decisions.
See More
